Business Context and Reporting Period
This Form 8-K filing by Artele Biosciences, Inc. (Nasdaq: ARTL) covers the reporting period of February 16, 2021. The company is incorporated in Nevada and maintains its principal executive offices in La Jolla, California.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The primary material event reported is the resolution of a listing deficiency:
- On February 16, 2021, the Company received formal notification from The Nasdaq Stock Market LLC confirming it had regained compliance with the Minimum Bid Price Rule (Nasdaq Listing Rule 5550(a)(2)).
- The requirement mandates a minimum bid price of at least $1.00 per share for common stock.
- Nasdaq confirmed that the matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No new risks, contingencies, or unusual items were disclosed in this specific report.
Investor Verification Checklist
- Verify the current trading price of ARTL common stock to ensure it remains above the $1.00 threshold.
- Confirm the status of the company's warrants (ARTLW) listed on Nasdaq.
- Review subsequent filings to ensure no new compliance notices have been issued by Nasdaq.